Should You Buy Atara Biotherapeutics Inc (ATRA) Stock After it Is Up 24.56% in a Week?

Atara Biotherapeutics Inc (ATRA) stock is higher by 24.56% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Atara Biotherapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATRA!

See Full ATRA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ATRA Stock Today?

Atara Biotherapeutics Inc (ATRA) stock is trading at $0.71 as of 9:34 AM on Thursday, Nov 30, an increase of $0.02, or 3.13% from the previous closing price of $0.69. The stock has traded between $0.69 and $0.77 so far today. Volume today is light. So far 1,782,660 shares have traded compared to average volume of 7,140,008 shares.

More About Atara Biotherapeutics Inc

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs. Click Here to get the full Stock Report for Atara Biotherapeutics Inc stock.